image credit: Freepik

Sotio Biotech, MSD Enter Clinical Trial Collaboration & Supply Agreement

December 8, 2021

Sotio Biotech, a clinical stage immuno-oncology company owned by PPF Group, has entered into a clinical trial collaboration and Supply Agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., through its subsidiaries, to evaluate the combination of SOT101, Sotio’s IL-15 superagonist, and MSD’s Keytruda (pembrolizumab) in patients with selected advanced/refractory solid tumors in the phase 2 Aurelio-04 study.

“SOT101 in combination with Keytruda has shown promising clinical Efficacy across multiple indications in our ongoing phase 1/1b Aurelio-03 study,” said Radek Špíšek, Ph.D., global CEO of Sotio.

Read More on Contract Pharma